Close Menu

NEW YORK – A team of German researchers in collaboration with Qiagen has built a workflow to analyze genomic and transcriptomic data in parallel from multiple analytes including circulating tumor cells (CTCs), circulating cell-free tumor DNA (cfDNA), and extracellular vesicles (EVs) from a minimal blood volume sample.

The team has now begun analyzing additional analytes in HER2-positive breast cancer patients and will present preliminary results at the American Association of Cancer Research Meeting in May.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.